{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-016452","form_type":"8-K","ticker":"ZVRA","cik":"0001434647","company_name":"ZEVRA THERAPEUTICS, INC.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.285134+00:00","generated_at":"2026-05-21T14:33:02.645989+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Zevra Q1 net revenue $20.4M, PRV sale nets $148M; net loss narrows to $3.1M","bullets":["Q1 2025 net revenue $20.4M (up from $3.4M YoY); MIPLYFFA contributed $17.1M, OLPRUVA $0.1M.","Net loss of $3.1M ($0.06 per share) vs. $16.6M loss ($0.40) in Q1 2024; operating expenses $22.8M.","Closed sale of Pediatric Rare Disease PRV for $150M gross; net proceeds $148.3M received Apr. 1, 2025.","Cash, equivalents and investments $68.7M at Mar 31; combined with PRV proceeds, pro-forma cash $217M.","MIPLYFFA: 13 new prescription enrollment forms in Q1 (122 total); market access 38% of covered lives."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-016452","json":"https://secwatch.observer/filing/0001437749-25-016452.json","markdown":"https://secwatch.observer/filing/0001437749-25-016452.md","text":"https://secwatch.observer/filing/0001437749-25-016452.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434647/000143774925016452/0001437749-25-016452-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434647/000143774925016452/zvra20250106_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T14:33:02.645989+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}